Burning Rock Biotech (BNR) has surged 405% over the past year, hitting a 2-year high on Wednesday. Valued at $209 million, BNR focuses on precision oncology using next-generation sequencing technology in Guangzhou, China. Barchart data shows BNR has a 100% “Buy” opinion and a Weighted Alpha of +82.77, with a 50-day moving average of $11.20 and RSI at 75.84. This highly speculative stock is not recommended for all investors.

Read more at Yahoo Finance: This Undiscovered Biotech Stock Has Quintupled in a Year and Just Hit New Highs